EDEN PRAIRIE, Minn., Oct. 12, 2021 /PRNewswire/ — NeuroOne Medical Applied sciences Company (Nasdaq: NMTC) (the “Firm”), a medical expertise firm targeted on bettering surgical care choices and outcomes for sufferers affected by neurological issues, in the present day introduced that it has commenced a proposed underwritten registered public providing of shares of its frequent inventory.
The entire shares of frequent inventory to be offered within the proposed providing can be offered by the Firm. As well as, the Firm intends to grant the underwriter a 30-day choice to buy as much as a further 15% of the shares of its frequent inventory offered within the providing. The proposed providing is topic to market and different situations, and there may be no assurance as as to whether or when the providing could also be accomplished, or as to the precise measurement or phrases of the providing.
The Firm intends to make use of the online proceeds from this proposed providing for working capital and different common company functions.
Craig-Hallum Capital Group is appearing as the only managing underwriter for the proposed providing.
The proposed providing is being made pursuant to a shelf registration assertion on Type S-3 (File No. 333-256830) that was declared efficient by the U.S. Securities and Alternate Fee (“SEC”), on June 14, 2021. A preliminary prospectus complement and accompanying prospectus regarding the proposed providing can be filed with the SEC and can be accessible on the SEC’s web site at www.sec.gov or by contacting Craig-Hallum Capital Group LLC, 222 South Ninth Road, Suite 350, Minneapolis, MN 55402, Attn: Fairness Capital Markets, phone: 612-334-6300 or by e-mail at [email protected]
This press launch doesn’t and shall not represent a proposal to promote or the solicitation of a proposal to purchase any securities, nor shall there be any sale of those securities in any state or different jurisdiction during which such provide, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or different jurisdiction. Any provide, if in any respect, can be made solely via a prospectus, together with a prospectus complement, forming part of the efficient registration assertion.
About NeuroOne
NeuroOne Medical Applied sciences Company is a developmental stage firm dedicated to offering minimally invasive and hi-definition options for EEG recording, mind stimulation and ablation options for sufferers affected by epilepsy, Parkinson’s illness, dystonia, important tremors, persistent ache as a consequence of failed again surgical procedures and different associated neurological issues that will enhance affected person outcomes and scale back procedural prices. For extra data, go to https://www.n1mtc.com.
Ahead Trying Statements
This press launch could embody forward-looking statements inside the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. Apart from statements of historic truth, any data contained on this presentation could also be a ahead–trying assertion that displays the Firm’s present views about future occasions and are topic to identified and unknown dangers, uncertainties and different elements that will trigger our precise outcomes, ranges of exercise, efficiency or achievements to be materially totally different from the knowledge expressed or implied by these forward-looking statements. In some circumstances, you’ll be able to establish ahead–trying statements by the phrases “could,” “may,” “will,” “may,” “would,” “ought to,” “count on,” “intend,” “plan,” “goal,” “anticipate,” “consider,” “estimate,” “predict,” “challenge,” “potential,” “goal,” “search,” “ponder,” “proceed” and “ongoing,” or the detrimental of those phrases, or different comparable terminology supposed to establish statements concerning the future. Ahead–trying statements embody statements associated to the proposed providing and anticipated use of proceeds. Though the Firm believes that we now have an affordable foundation for every forward-looking assertion, we warning you that these statements are primarily based on a mixture of details and elements presently identified by us and our expectations of the longer term, about which we can’t be sure. Our precise future outcomes could also be materially totally different from what we count on as a consequence of elements largely outdoors our management, together with dangers and uncertainties associated to market and different situations, the satisfaction of customary closing situations associated to the proposed public providing, the influence of common financial, business or political situations in america or internationally and people described below the heading “Threat Components” in our filings with the Securities and Alternate Fee. These ahead–trying statements converse solely as of the date of this press launch and the Firm undertakes no obligation to revise or replace any ahead–trying statements for any purpose, even when new data turns into accessible sooner or later.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-announces-proposed-public-offering-of-common-stock-301398697.html
SOURCE NeuroOne Medical Applied sciences Company
